Germantown, MD, United States of America

Palanisamy Kanakaraj

USPTO Granted Patents = 5 

 

 

Average Co-Inventor Count = 4.4

ph-index = 4

Forward Citations = 89(Granted Patents)


Location History:

  • Rockville, MD (US) (2012 - 2014)
  • Germantown, MD (US) (2013 - 2016)

Company Filing History:


Years Active: 2012-2016

Loading Chart...
Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: **Innovator Spotlight: Palanisamy Kanakaraj**

Introduction

Palanisamy Kanakaraj is a prominent inventor based in Germantown, MD, who has made significant contributions to the field of biopharmaceuticals. With a total of five patents to his name, Kanakaraj's work has been instrumental in the development of innovative treatments aimed at addressing complex medical conditions.

Latest Patents

Among his latest contributions, Kanakaraj has developed humanized antibodies against TL1A, specifically targeting TNF superfamily member 15 (TNFSF15), also referred to as TL1A. These humanized antibodies exhibit the potential to act as antagonists and can be utilized to treat or diagnose various conditions associated with TL1A function. The disclosed methods provide insights into creating and employing these anti-TL1A antibodies, demonstrating Kanakaraj's dedication to advancing therapeutic options in the medical field.

Career Highlights

Palanisamy Kanakaraj is currently employed at Teva Biopharmaceuticals USA, Inc., where he continues to push the boundaries of biopharmaceutical innovation. His work focuses on creating novel therapies that leverage cutting-edge scientific developments to improve patient outcomes.

Collaborations

Throughout his career, Kanakaraj has collaborated with several esteemed colleagues, including Rodger G. Smith and Viktor Roschke. These partnerships enhance the collaborative efforts within the scientific community and aid in driving forward the research and development of new biomedical therapies.

Conclusion

In summary, Palanisamy Kanakaraj is a distinguished inventor whose work in developing humanized antibodies offers promising avenues for treating and diagnosing conditions related to TL1A function. His contributions at Teva Biopharmaceuticals USA, Inc. and collaborations with fellow innovators underscore his vital role in the advancement of biopharmaceuticals. Through his continued efforts, Kanakaraj exemplifies the spirit of innovation that drives progress in the healthcare sector.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…